Healthcare stocks experienced a significant rally on Thursday, driven by Abbott Laboratories' (NYSE: ABT) outsized gains and mixed results from managed-care companies. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) climbed 2.2% to $161.81, outpacing the broader market as the SPDR S&P 500 ETF Trust (NYSEARCA: SPY) slipped 0.5% to $750.71.
Abbott's Surge Defies Earnings Expectations
Abbott Laboratories posted a 10.9% jump in its share price, a reaction that far exceeded its modest earnings beat. The medical device and diagnostics company reported adjusted earnings per share of $1.31, compared to consensus estimates of $1.28—a 2.3% beat. The stock's dramatic move suggests that investors had been bracing for worse news regarding medtech demand, particularly amid concerns over expiring pandemic-era Affordable Care Act subsidies that could weaken procedure volumes.
Abbott raised its 2026 adjusted EPS guidance to a range of $5.45 to $5.60 per share, with the midpoint increasing 0.8% from the previous company range. The quarterly results provided reassurance, with medical-device sales rising 9% to $5.85 billion and reported diagnostics sales climbing 42% to $3.09 billion, boosted by the Exact Sciences acquisition. On a comparable basis, diagnostics growth was 2.9%.
Chief Executive Robert Ford dismissed the notion that coverage losses would significantly impact demand, calling it a "flawed assumption" and noting that chronic-disease patients are less likely to forgo insurance. This sentiment was echoed by Johnson & Johnson (NYSE: JNJ), whose medtech executive Tim Schmid stated Wednesday that "procedure volumes continue to be stable," although J&J's device sales still missed estimates by about $40 million.
UnitedHealth Shines Amid Cost Ratio Improvement
UnitedHealth Group (NYSE: UNH) rose 2.6% after reporting a much larger earnings beat. The insurer posted adjusted EPS of $6.38 against consensus of $4.90, a roughly 30% above expectations. UnitedHealth's medical-cost ratio improved to 86.7%, beating consensus by 177 basis points and down from 89.4% a year earlier. The company raised its adjusted EPS guidance to $19.50-$20.00 per share, up from its previous outlook of more than $18.25. Optum, its health services segment, saw operating income rise 29% to $4.0 billion.
However, UnitedHealth experienced membership declines, serving 48.5 million people—down 525,000 sequentially—with Medicare Advantage enrollment falling 965,000 since year-end.
Diverging Managed-Care Stocks
While UnitedHealth gained, other managed-care stocks faced headwinds. Elevance Health (NYSE: ELV) fell 3.7% despite raising its 2026 profit floor by 25 cents on Wednesday. Baird analyst Michael Ha attributed the decline to elevated investor expectations. Humana (NYSE: HUM) lost 2.8%, while CVS Health (NYSE: CVS) managed a 1.1% gain.
Risks and Outlook
Despite the positive sentiment, risks remain. Abbott's nutrition sales fell 3.1%, posing a clear challenge. UnitedHealth's membership declines could restrain revenue growth, and further coverage losses might eventually impact procedure volumes. Thursday's trade favored companies that removed specific earnings risks, with Abbott easing procedure concerns while managed-care stocks remained dependent on each company's cost ratio and membership trends.
